Dr Gregory Lunceford is a recognizable name in precision medicine and clinical research, particularly for his work on pharmacogenomics and cardiovascular risk. Readers often search for his professional background and current roles to understand how his expertise influences patient care and drug development.
Below is a structured overview of Dr Gregory Lunceford profile, career timeline, specialties, and public contributions. This summary provides quick reference points for patients, collaborators, and industry professionals who want to confirm how his experience aligns with specific projects or institutions.
| Full Name | Gregory A Lunceford | Primary Specialty | Clinical Pharmacology / Pharmacogenomics |
|---|---|---|---|
| Current Role | Senior Scientist and Director at a major pharmaceutical research division | Key Focus Area | Cardiovascular genetics, drug metabolism, therapeutic optimization |
| Notable Affiliations | Academic medical centers and industry research groups in the United States | Board Certification | Clinical Pharmacology, with subspecialty focus in clinical investigation |
| Career Start | Board certification and early research roles in the late 1990s | Recent Projects | Implementation of genotype-guided dosing in large healthcare systems |
| Primary Impact | Improving safety and efficacy of cardiovascular medications through genetic data |
Early Career and Education
Dr Gregory Lunceford completed rigorous training in clinical pharmacology, combining laboratory science with direct patient care. His educational background emphasizes translational research, allowing him to move smoothly from bench studies to bedside applications. This phase established the foundation for later leadership in pharmacogenomics initiatives.
Professional Roles and Research Focus
Over the years, Dr Gregory Lunceford has held senior positions where he directed pharmacogenomics programs and coordinated large scale studies. His research concentrates on cardiovascular drugs, where genetic markers help predict response and adverse events. By linking genomic data with electronic health records, he supports initiatives that reduce trial and error in prescribing.
Key Contributions to Pharmacogenomics
Dr Gregory Lunceford has been instrumental in demonstrating how standardized genetic testing can streamline medication selection. His work often highlights cost savings and improved outcomes when providers use genotype information early in treatment planning. Collaborations with health systems have enabled broader adoption of these practices across regions.
Industry Leadership and Collaborations
In industry settings, Dr Gregory Lunceford bridges clinical insights and drug development teams. He helps design trials that enroll genetically enriched populations, ensuring that results reflect real world diversity. These collaborations strengthen the evidence base for label claims and support regulatory strategies.
Legacy and Ongoing Work
Dr Gregory Lunceford legacy centers on advancing precision medicine in everyday practice, ensuring that genetic insights become routine considerations in drug therapy. Current efforts focus on scaling these approaches across diverse populations and therapeutic areas, reinforcing measurable improvements in safety and effectiveness.
- Focus on pharmacogenomics to optimize cardiovascular drug therapy
- Leadership in translating research into clinical decision support tools
- Collaboration with health systems for scalable implementation
- Commitment to reducing prescribing errors through genetic data
- Contributions to regulatory strategies and label claims for genotype guided medications
FAQ
Reader questions
What specific areas does Dr Gregory Lunceford specialize in?
He specializes in clinical pharmacology and pharmacogenomics with an emphasis on cardiovascular medications and genetic guided dosing.
How does Dr Gregory Lunceford contribute to patient care?
His work translates genetic data into practical prescribing tools that help clinicians choose safer and more effective medications for individual patients.
What roles has Dr Gregory Lunceford held in research organizations? He has led pharmacogenomics programs, directed clinical investigation units, and collaborated on large scale studies in both academic and industry environments. Can healthcare providers use his research for genotype guided prescribing today?
Yes, his studies and implementations provide actionable frameworks that health systems can adopt to integrate genetic testing into routine medication management.